BMRA (Biomerica) Moat Score: 3/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMRA Biomerica Inc BMRA
50 GF Score
Price $1.49
GF Value $2.18
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Biomerica Moat Score?

Biomerica BMRA -6.28% 50 Moat Score is 3 as of Aug. 01, 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Biomerica ranks better than 75.66% on this metric.

Biomerica has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Biomerica has No Moat: Biomerica Inc has limited market leadership and lacks significant customer switching costs or strong brand loyalty. The company operates in a competitive industry with minimal regulatory barriers and does not possess significant intellectual property or cost advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Biomerica might have No Moat - Very weak/transient advantages.

Biomerica  (NAS:BMRA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Biomerica Moat Score Related Terms

BMRA vs WOK, ALURD, ITOC: Moat Score Comparison

For the Medical Devices subindustry, Biomerica's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomerica Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Moat Score distribution charts can be found below:

* The bar in red indicates where Biomerica's Moat Score falls into.


BMRA
50GF Score
Biomerica Inc BMRA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Biomerica (BMRA) has a Moat Score of 3 as of Aug. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Biomerica ranks #204 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 24.3%.
Is Biomerica's Moat Score too high?
Biomerica's current Moat Score is 3. Based on the distribution chart, Biomerica ranks #204 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biomerica has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Moat Score compare to WOK and ALURD?
According to the Medical Devices & Instruments industry distribution chart, Biomerica ranks #204 out of 838 companies for Moat Score. This places Biomerica in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Biomerica's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $1.49 — trading 31.7% below its estimated fair value. The current Moat Score is 3. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Biomerica (BMRA), the current Moat Score is 3 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biomerica (BMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Biomerica stock appears to be undervalued. The current stock price of $1.49 is trading 31.7% below its estimated GF Value™ of $2.18. GuruFocus considers Biomerica to be Possible Value Trap.

Key valuation signals for BMRA:

  • Moat Score: 3
  • GF Value™: $2.18 vs. price of $1.49 (31.7% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biomerica Business Description

Address 17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score

Get the complete analysis for BMRA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$2.18
GF Value